Yosef Shaul

Dr. Yosef Shaul

Department of Molecular Genetics, Weizmann Institute of Science, Rehovot 76100, Israel
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in Genes & Development
Verified
Journal Article
Open access
PDF file
GAGad Asher
Gad Asher
PTPeter Tsvetkov
Peter Tsvetkov
CKChaim Kahana
Chaim Kahana
Yosef ShaulYosef Shaul
Yosef Shaul
Protein degradation is an essential and highly regulated process. The proteasomal degradation of the tumor suppressors p53 and p73 is regulated by both polyubiquitination and by an ubiquitin-independent process. Here, we show that this ubiquitin-independent process is mediated by the 20S proteasomes and is regulated by NQO1. NQO1 physically interacts with p53 and p73 in an NADH-dependent manner and protects them from 20S proteasomal degradation. Remarkably, the vast majority of NQO1 in cells is found in physical association with the 20S proteasomes, suggesting that NQO1 functions as a gatekeeper of the 20S proteasomes. We further show that this pathway plays a role in p53 accumulation in response to ionizing radiation. Our findings provide the first evidence for in vivo degradation of p53 and p73 by the 20S proteasomes and its regulation by NQO1 and NADH level.

26 February 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
GAGad Asher
Gad Asher
JLJoseph Lotem
Joseph Lotem
RKRachel Kama
Rachel Kama
LSLeo Sachs
Leo Sachs
Yosef ShaulYosef Shaul
Yosef Shaul
Wild-type p53 is a tumor-suppressor gene that encodes a short-lived protein that, upon accumulation, induces growth arrest or apoptosis. Accumulation of p53 occurs mainly by posttranslational events that inhibit its proteosomal degradation. We have reported previously that inhibition of NAD(P)H: quinone oxidoreductase 1 (NQO1) activity by dicoumarol induces degradation of p53, indicating that NQO1 plays a role in p53 stabilization. We now have found that wild-type NQO1, but not the inactive polymorphic NQO1, can stabilize endogenous as well as transfected wild-type p53. NQO1-mediated p53 stabilization was especially prominent under induction of oxidative stress. NQO1 also partially inhibited p53 degradation mediated by the human papilloma virus E6 protein, but not when mediated by Mdm-2. Inhibitors of heat shock protein 90 (hsp90), radicicol and geldanamycin, induced degradation of p53 and suppressed p53-induced apoptosis in normal thymocytes and myeloid leukemic cells. Differences in the effectiveness of dicoumarol and hsp90 inhibitors to induce p53 degradation and suppress apoptosis in these cell types indicate that NQO1 and hsp90 stabilize p53 through different mechanisms. Our results indicate that NQO1 has a distinct role in the regulation of p53 stability, especially in response to oxidative stress. The present data on the genetic and pharmacologic regulation of the level of p53 have clinical implications for tumor development and therapy.

1 April 2003 in Hepatology
Verified
Journal Article
Closed access
PDF file
ASAmir Shlomai
Amir Shlomai
Yosef ShaulYosef Shaul
Yosef Shaul
RNA interference (RNAi) is the process of sequence–specific gene silencing, initiated by double–stranded RNA (dsRNA) that is homologous in sequence to the target gene. Because it has been shown that RNAi can be accomplished in cultured mammalian cells by introducing small interfering RNAs (siRNAs), much effort has been invested in exploiting this phenomenon for experimental and therapeutic means. In this study, we present a series of experiments showing a significant reduction in hepatitis B virus (HBV) transcripts and proteins in cell culture, as well as in the viral replicative forms, induced by siRNA–producing vectors. The antiviral effect is sequence–specific and does not depend on active viral replication. In conclusion, our data suggest that RNAi may provide a powerful therapeutic tool, acting both on replication–competent and on replication–incompetent HBV. (Hepatology 2003;37:764–770.)

13 September 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
GAGad Asher
Gad Asher
JLJoseph Lotem
Joseph Lotem
LSLeo Sachs
Leo Sachs
CKChaim Kahana
Chaim Kahana
Yosef ShaulYosef Shaul
Yosef Shaul
The tumor suppressor p53 is a labile protein whose level is known to be regulated by the Mdm-2–ubiquitin–proteasome degradation pathway. We have found another pathway for p53 proteasomal degradation regulated by NAD(P)H quinone oxidoreductase 1 (NQO1). Inhibition of NQO1 activity by dicoumarol induces p53 and p73 proteasomal degradation. A mutant p53 (p53 [22,23] ), which is resistant to Mdm-2-mediated degradation, was susceptible to dicoumarol-induced degradation. This finding indicates that the NQO1-regulated proteasomal p53 degradation is Mdm-2-independent. The tumor suppressor p14 ARF and the viral oncogenes SV40 LT and adenovirus E1A that are known to stabilize p53 inhibited dicoumarol-induced p53 degradation. Unlike Mdm-2-mediated degradation, the NQO1-regulated p53 degradation pathway was not associated with accumulation of ubiquitin-conjugated p53. In vitro studies indicate that dicoumarol-induced p53 degradation was ubiquitin-independent and ATP-dependent. Inhibition of NQO1 activity in cells with a temperature-sensitive E1 ubiquitin-activating enzyme induced p53 degradation and inhibited apoptosis at the restrictive temperature without ubiquitination. Mdm-2 failed to induce p53 degradation under these conditions. Our results establish a Mdm-2- and ubiquitin-independent mechanism for proteasomal degradation of p53 that is regulated by NQO1. The lack of NQO1 activity that stabilizes a tumor suppressor such as p53 can explain why humans carrying a polymorphic inactive NQO1 are more susceptible to tumor development.

22 August 2006 in BioEssays
Verified
Journal Article
Closed access
PDF file
GAGad Asher
Gad Asher
NRNina Reuven
Nina Reuven
Yosef ShaulYosef Shaul
Yosef Shaul

17 November 2006 in Cell Death & Differentiation
Verified
Journal Article
Closed access
DLDan Levy
Dan Levy
YAY Adamovich
Y Adamovich
NRN Reuven
N Reuven
Yosef ShaulYosef Shaul
Yosef Shaul